Intro
By this point in the series, most readers are arriving at the same question.
So what do I do?
That is the right question to ask, and it deserves a real answer. The answer is structured differently than readers may expect, because the framework this series has been building does not lend itself to a prescription. It lends itself to a posture, and to a sequence of practical steps that follow from the posture.
Three steps, in order. Look. Ask. Support.
---
First, Look
Before anything else, look at the lab panel — your own, or your patient's — with the framework this series has been describing.
Find the directly measured LDL-C. Most modern panels include it alongside the calculated value. If yours does not, request it. The Friedewald-calculated VLDL is the noisy estimate the entire series has been working to move past, and the cleaner number is available with a single ordering change.
Subtract the directly measured LDL-C and the HDL-C from the total cholesterol. What is left is VLDL-C, derived without the equation that has been distorting the signal.
Then look at the triglycerides, and at the ApoB if it is available, and at the fasting glucose and the HbA1c. Read them together, with the liver at the center. The question is not "are any of these numbers high in isolation." The question is what story they are telling about the operating state of the liver.
This is the first practical step. Not a treatment. Not a supplement. A way of looking.
For many readers, this single change in how they read the lab panel will be the most consequential thing the series has offered.
---
Then, Ask
Once the panel has been read with the upstream question in mind, the next step is to ask that question out loud.
For patients, the question is for the clinician. *Given this pattern, what is the liver doing?* Not as a challenge, but as a way of inviting the conversation upstream. Most clinicians, presented with the question respectfully, will engage with it — particularly if the patient also has signs of insulin resistance, hepatic steatosis on imaging, or the metabolic and lipid pattern this series has been describing.
For clinicians, the question is for themselves and for the patient. *What is producing this pattern?* It is the question that reframes a lipid panel from a collection of risk numbers to be managed individually, into a coherent readout of an upstream condition that can be addressed.
The question has practical consequences. Once it has been asked, the next decisions — what to investigate, what to prioritize, what to monitor — organize themselves differently.
---
Then, Support
The third step is the one this series has been most careful about, and the one that requires the most discipline.
The hepatic state that produces an elevated VLDL is the result of multiple inputs. Substrate load. Insulin signaling. Hepatic fat accumulation. The supply of structural components the liver needs to assemble and export particles cleanly. Each of these is, to varying degrees, modifiable.
What modifies them well is the part this series has deliberately left to other content.
The reason is straightforward. The educational case for the framework — VLDL as the A1C of the liver, the cascade across organs, the unification of what looks like five specialty conversations into one upstream signal — has to be established on its own merits. If the educational content drifts into promotion of any specific intervention, the framework becomes harder to trust. Readers who would otherwise have absorbed the science begin to wonder whether the science was constructed to serve the promotion.
So this series has stopped at the framework.
What to do clinically — which dietary patterns reduce hepatic substrate load, which forms of physical activity improve insulin signaling at the liver, which nutritional and pharmacologic supports can address specific hepatic limitations like inadequate phosphatidylcholine for VLDL assembly — all of that exists. Some of it is well-established. Some of it is the focus of our other work, including the formulation rationale page on this site and the practitioner-facing content available there.
The work of supporting the liver is real, and it has tools. This series has stayed upstream of those tools deliberately, so that when readers do encounter them, they encounter them with the framework already in place.
---
What the Series Has Been Trying to Do
Twelve posts ago, this series began with a number that was sitting quietly on the lab panel and was not being read correctly.
The argument has been that VLDL, properly understood and properly measured, is something more useful than a secondary lipid value. It is the integrated readout of how the liver has been operating. It carries information about substrate, about insulin signaling, about the export system, about the lipid environment that the kidney, the brain, the artery, and the pancreas are all living in.
Read that way, VLDL is not a risk factor to be reduced. It is a signal to be heard.
The clinician who hears it can ask better questions. The patient who hears it can advocate for those questions to be asked. And the medical conversation, slowly, can begin to reorganize itself around the upstream condition rather than around the downstream consequences that have, for too long, been treated as if they were independent diseases.
That is the work this series has been trying to do.
VLDL is the A1C of the liver.
Read it that way, and everything downstream begins to make sense.